Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial - Poll - MDSpire

Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial

  • By

  • Symeon Savvopoulos

  • Anastasia Papadopoulou

  • Georgios Karavalakis

  • Ioanna Sakellari

  • Grigorios Georgolopoulos

  • Christos Argyropoulos

  • Evangelia Yannaki

  • Haralampos Hatzikirou

  • June 4, 2026

  • 0 min

Share

Original Source(s)

Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial

  • by Symeon Savvopoulos, Anastasia Papadopoulou, Georgios Karavalakis, Ioanna Sakellari, Grigorios Georgolopoulos, Christos Argyropoulos, Evangelia Yannaki, Haralampos Hatzikirou

  • June 4, 2026

Related Content

From immunological mechanisms to targeted therapies: a bibliometric analysis in the domain of research concerning neutrophil extracellular traps and pulmonary diseases (2006–2025)

Decision Aids for Vaccination in an Era of Medical Freedom

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.